Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 3
Submit an article Journal homepage
21
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Bone Turnover Following Autologous Transplantation in Multiple Myeloma

Richard E. Clark Department of Haematology
&
William D. Fraser Department of Clinical Chemistry, Duncan Building, University of Liverpool, Prescot St, Liverpool L7 8XP, UK
Pages 511-516 | Published online: 01 Jul 2009

  • Moulopoulos, L.A. and Dimopoulos, M.A. (1997) "Magnetic resonance imaging of the bone marrow in hematologic malignancies", Blood 90, 2127-2147.
  • Moulopoulos, L.A., Dimopoulos, M.A., Smith, T.L., Weber. D.M., Delusalle, K.B., Libshitz, H.J. and Alexanian, R. (1995) "Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma". J. Clin. Oncol. 13, 251-256.
  • Myeloma Trialists Collaborative Group (1998) "Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials", J Clin. Oncol. 16, 3832-3842.
  • Belch, A.R., Bergsagel, D.E., Wilsou, K., O'Reilly. S., Wison, J., Sutton, D., Paler, J., Johnston. D. and Xee. B. (1991) "Effect of daily etidronate on the osteolysis of multiple myeloma". J. Clin. Oncol. 9. 1397-1402.
  • Attal, M., Harousseau, J.L., Stoppa. A.M., Sotto. J.J., Fuzibet. J.G., Rossi. J.F., Casaisus, P., Maisonneuve. H., Facon. T., lfrah, N., Payen, C. and Bataille. R. (1996) "A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma". New Engl. J Med. 335, 91-97.
  • Fermand, J.P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro. M., Pertuiset, E., Dreyfus. K. Marielle. X., Boccacio, C. and Brouet. J.C. (1998) "High-dose therapy and nutologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial", Blood. 31, 31-3136.
  • Mundy, G.R., Raisz, L.G., Cooper. R.A., Schlechter. G.P. and Salmon, S.E. (1974) "Evidence for the secretion of an osteoclust stimulating factor in myeloma". New Eng. J. Med. 291, 1041-1046.
  • Bataille, R., Chappard. D., Marcelli. C. Dessauw, P., Sany. J., Baldet. P. and Alexandre, C. (1989) "Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease". J. Clin. Oncol, 7, 1909-1914.
  • Bataille, R., Chappard, D. and Basle. M-F. (1996) "Quantiliable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies". Blood 87, 4762-4769.
  • Taube, T., Beneton, M.N.C., McCloskey, E.V., Rogers. S., Greaves. M. and Kanis. J.A. (1992) "Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption". Eur. J. Haematol. 49, 192-198.
  • Uchiyama, H., Barut. B.A., Mohrbacher. A.H., Chauhan. D. and Anderson. K.C. (1993) "Adhesion of human myeloma-derived cell fines to bone marrow stromal cell., stimulates interIeukin-6 secretion". Blood 82, 3712-3720.
  • Tricot, G. (2000) "New insights into the role of microenvironment in multiple myeloma", Lancer 355, 248-250.
  • Garrert, I.R., Dune. B.G.M., Nedwin. O.E., Gillespie, A., Bringman, T., Sabatini, M., Bertolini. D.R. and Mundy. G.R. (1987) "Production of lymphotoxin, a bone resorting cytokine. by cultured human myeloma cells". New Engl, J. Med. 317, 526-532.
  • Kawano, M., Tanaka, H., Ishikawa, H., Nobuyoshi, M., Iwato, K., Asaoku. H., Tanabe. O and Kuramoto. A. (1989) "Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma". Blood 73, 2145-2148.
  • Carter, A., Merchav, S., Silvian-Draxier. J. and Tatarsky. I (1990) "The role of laterleukin-1 and tumour necrosis factor á in human multiple myeloma", Br. J. Haematol, 74, 424-431.
  • Roodman, G.D. (1992) "lnterleukin-6: an osteotropic factor?". J. Bone Min. Res. 7, 475-478.
  • Chauhan, D., Kharbanda, S., Ogata, A. Urashima. M., Teoh, G., Robertson, M., Kufe. D.W. and Anderson. K.C. (1997) "Interleukin-6 inhibits Fax-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells", blood 89. 227-234.
  • Ogata, A., Chauhan, D., Teoh. G., Treon. S.P., Urashima. M., Schlossman. R.L. and Anderson. K.C. (1997) "IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade" J Immunol. 159, 2212-2221.
  • Treon, S.P. and Anderson. K.C (1998) "Interleukin-6 in multiple myeloma and related plasma cell dyserasias". Curr. Opin. Hentatol 5, 42-48.
  • Simonet, W.S., Laccy, D.L., Dunstan. C.R., Kelley. M., Chang, M.S., Luthy. R., Nguyen, H.Q., Wooden. S. Bennett, L., Boone. T., Shimamoto. G., DeRose. M., Elliott, R., Colombero. A., Tan. H.L., Trail, G., Sullivan, J., Davy. E. Bucay. N., Renshaw-Gegg. L., Hughes. T.M., Hill. D., Pattison. W., Campbell, P., Boyle. W.J., et al. (1997) "Osteoprotegerin: a novel secreted protein involved in the regulation of hone density". Cell 89, 309-319.
  • Tsuda, E., Goto, M., Mochizuki, S., Yano. K., Kobayashi. K, Morinaga, T. and Higashio, K. (1997) "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis". Biachem. Biophys. Rex. Common. 234. 137-142.
  • Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi. K., Kinosaki. M., Mochizuki. S. Tomoyasu. A., Yauo. K., Goto. M., Murakami, A., Tsuda. E., Morioaga. T., Higashio. K., Udagawa, N., Takahashi. N and Suda. T. (1998) "Osteoclast differentiation factor is a ligand lor osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL". Proc: Nat. Acad Sci. USA 95. 3597-3602.
  • Lacey, D.L., Timms, E., Tan, HI., Kelley. M.J., Dunstan. C.R., Burgess. T. Elliott, R., Colombero. A. Elliott. G., Scully, S., Hsu. H., Sullivan. J., Haukins, N., Davy. E., Capparelli, C., Eli, A., Qian. Y.X., Kaufman, S., Sarosi, I., Shalhoub. V., Senaldi. G., Guo. J., Delaney, J. and Boyle, W.J. (1998) "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", cell, 165-176
  • Matsuzaki, K., Udagawa. N., Takahashi, N., Yamaguchi. K., Yasuda, H., Shima. N., Morinaga, T., Toyama. Y., Yabe. Y., Higushio. K. and Suda. T. (1998) "Osteoclast differentiation factor (ODF) induces ostcoclast-like cell formation in human peripheral blood mononuclear cell cultures". Biochem, Biophys: Res. Common 246, 199-204.
  • Raje, N. and Anderson, K.C. (2000) "Introduction: the evolviug role of bisphosphonate therapy in multiple myeloma". Blood 96. 381-383
  • Collin-Osdoby, P., Rotlie, L., Anderson. R. Nelson. M., Maloney. W. and Osdoby. P. (2001) "Receptor activator of nf-kappa b and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines and role in human osteoclastogenesis". J Biol. Chem. 276, 20659-20672.
  • Udagawa, N., Takanashi, N., Yasuda, H., Mizuno. A., ltoh, K., Ueno. Y., Shinki. T., Gillespie, M.T., Martin. T.J., Higashio, K. and Suda, T. (2000) "Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function". Endocrinol. 141, 3478-3484.
  • Shalboub, V, Haust. J. Boyle. W.J., Dunstan. C.R., Kelley. M., Kaufman. S., Seully. S., Van. G. and Lacey. D.L. (1999) "Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from hurran peripheral blood mononuclear cell precursors", J Cell Biochem. 72, 251-261.
  • Shipman, C.M., Holen, I. Lippitt. J.M., Vandenberghe, E. and Croucher. P.I. (2000) "Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor. RANKL", Blond 96. p 360a. (abstract).
  • Pearse R.N., Sordillo, E.M., Yaccoby. S., Wong. B.R., Liau. D.F., Colman. N., Michaeli. J., Epstein, J. and Choi, Y. (2000) "Administration of the TRANCE-antagonist TR-FC limits myeloma-induced bone destruction". Blood 96, 549a.
  • Michigami, T, Shimizu, N., Williams. P.J., Niewolna. M., Dallas. S.L., Mundy. G.R. and Yoneda, T, (2000) "Cell-cell contact between marrow stromal cells and myeloma cells via VCAM 1 and alpha(4)betal(l)-integrin enhances production of osteoelast-stimulating activity". Blood 96, 1953-1960.
  • Xu. J., Tan. J.W., Huang, L., Gao. X.H., Laird, R., Liu, D. Wysocki. S. and Zheng, M.H. (2000) "Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of XFkappaB ligand". J. Baue Min. Res. 15, 2178-2186.
  • Borset, M., Hjertner, O., Yaccoby, S., Epstein. J. and Sanderson. R.D. (2000) "Syndecan-l is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparinbinding proteins". Blood 96, 2528-2536.
  • Surdillo, E.M., Wong, B.R., Liau. U.K., Colman. N., Michaeli. J., Choi, Y. and Pearse, S.N. (2000) "Multiple myeloma disrupts the TRANC/OPG cytokine axis", Blood 96, 549a. (abstract).
  • Komine, M., Kukita, A., Kukita. T. Ogata. Y., Holokebuchi. T. and Kohashi. O. (2001) 'Tumor necrosis factor-á cooperates with receptor activator of nuclear factor ?B ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture". Bone 28, 474-483.
  • Bellamy, W.T., Richter. L., Frutiger. Y. and Gropan. TM. (1999) "Expression of vascular endothelial growth factor and its receptors in hematopoictic malimancies". Cancer Res. 59, 728-733.
  • Singhal, S., Mehta. J. Desikan, R., Avers, D., Roberson. P., Eddlemon. P., Munshi. N., Anaissie. E., Wilson. C-. Dhodapkar, M., Zeddis, J. and Barlogie. B. (1999) "Amitumour activity of thalidomide in refractory multiple myeloma". New Engl. J. Med 341, 1565-1571.
  • Raie, N. and Anderson. K.C. (1999) "Thalidomide-a revival story". New Engl. J. Med. 341, 1606-1609
  • Niida, S., Kaku, M. Amano. H., Yoshida. H., Kataoka. H., Nishikawa. S., Tanne, K., Maeda, N., Nishikawa, S. and Kodama. H. (1999) "Vascular endothelial growth factor can substitute for macrophage colony stmulating factor in the support of osteoclast bone resorption", J. Esper Med. 190, 293-298.
  • Girasole, G., Passeri, G., Jilka, R.L. and Manolagas, S.C. (1994) "Interieukin-11 : A new cytokine critical for ostcoclast development" J. Clin. Invest. 93, 1516-1524.
  • Russell, R.G and Rogers. M.J. (1999) "Bisphosphonates: from the laboratory to the clinic and back again". Bone 25, 97-106.
  • Amin, D., Cornell, S A., Gustafson, S.K., Needle. S.J., Ullrich. J.W., Bilder. G.E. and Perrone. M.H. (1992) "Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis", J. Lipid Res, 33, 1657-1663.
  • Coxon, P.P., Helfrich, M.H., Van t Hof. R.J., Sebti. S.M., Ralston. S.H., Hamilton. A.D. and Rogers. M.J. (2000) "Protein geranylgeranylation is requirec for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298". J. Bone Min. Res 15, 1467-1476.
  • Gibbs, J.B and Oliff. A. (1997) "The potential of famesyltransferase inhibitors as cancer chemotherapeutics", Ann. Rev. Pharmacol. Toxicol. 37, 143-166.
  • Benford, H.L., Frith, J.C., Auriola. S., Monkkonen. J. and Rogers, M.J. (1999) "Farnesol and geranylgeraniol prevent activation of caspascs by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs". Mol. Phamaral. 56, 131-140.
  • Shipman, C.M., Rogers. M.J., Apperley. J.F., Russell. R.G. and Croucher, P.I. (1997) "Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity". Br J. Haematol. 98, 665-672.
  • Shipman, C.M., Croucher. P.I., Russell, R.C., Helfrich, M.H. and Rogers. M.J. (1998) "The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway". Cancer Res. 58, 5294-5297.
  • Derenne, S., Amiot. M., Barille, S., Collette, M., Robillard, N., Berthaud. P, Harousseau. J.L. and Bataille, R. (19991 "Zoledronate is a potent inhibitor of myeloma cell growth and secretion of 1L-6 and MMP-I by the tumoral environment". J. Hone Min. Res. 14. 2048-2056.
  • Tassone, P., Forciniti. S., Galca, E., Morrone. G., Turco. M.C., Martinelli, V., Tagliaferri, P. and Venuta. S. (2000) "Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines". Leukemia 14. 841 -844.
  • Kunzmann, V., Bauer, E., Feurle, J., Weissinger. F., Tony, H.P. und Wilhelm, M. (2000) "Stimulation of -yS T-cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma". Blood 96, 384-392.
  • [5I] Lahnnen, R., Laakso. M., Palva, I., Virkkunen, P. and Elomaa, 1. (1992) "Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma". Lancet 340, 1049-1052.
  • Berenson, J.R., Lichcnstein, A., Porter. L., Dimopoulos. M.A., Borodani. R., George, S., Lipton. A., Keller, A., Ballesier. O., Kovacs, M.J., Blacklock. H.A., Bell. R., Simeone. J., Reilsma. D.J., Hefferman. M., Seaman. J. and Knight. R.D. (1996) "Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma". New Engl. J. Med. 334, 488 493.
  • Berenson, J.R. Lichtenstein. A., Porter. L., Dimopoulos. M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester. O., Kovaes. M., Blacklock. H., Bell. R., Simeone. J.F., Reitsma. D.J., Heffernan, M., Seaman. J. and Knight, R.D. (1998) "Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group". J. Clin. Oncol. 16, 593-602.
  • McCloskey, E.V., MacLennan. I.C.M., Drayson. M.T., Chapman. C., Dunn, J. and Kants. J. A. (1998) "A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma", Br: J. Haematol. 100, 317-325.
  • Kanis, J.A. and McCloskey, E.V. (2000) "Bisphosphonates in multiple myeloma". Cancer 88, 3022-3032.
  • Fraser, W.D. (1998) "The collagen crosslinks pyridinoline and deoxypyridinoline: a review of their biochemistry, physiology, measurement and clinical applications". J. Clin. Ligand Assay 21, 102-110.
  • Woitge, H.W., Pecherstorfer, M., Horn. E., Keck. A.V., Diel. I.J., Bayer, P., Ludwig. H., Ziegler. R. and Seibel. M.J. (2001) "Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma", Br J. Cancer 84, 344-351.
  • Woitge, H.W., Pecherstorfer. M., Li, Y., Keck. A-V. Horn. E., Ziegler, R. and Seihet, M.J. (1999) "Novel serum markers of hone resorption: clinical assessment and comparison with established urinary indices". J. Hone Min. Res. 14, 792-801.
  • Parfitt, A.M., Simon. L.S., Villanueva, A.R. and Krane. S.M. (1987) "Procollagen type 1 carboxy-terminal extension peptide in serum as u marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase". J. Bone Min. Res. 2, 427-436.
  • Abildgaard, N., BEndix-HansEn, K., Kristonsen, J.E., VejlgAard. T., Risteli. L., NielsEn. J.L. and Heickendorff. L. (1997) "Bone marrow fibrsis And disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum", Br. J. Haematol. 99, 641-648.
  • Pecherstorfer, M., Seibel, M.J., Woitge. H.W., Horn. K., Schuster. J., Neuda. I., Sagaster. P., Köhn. H., Bayer. P., Thiebaud. D. and Ludwig. H. (1997) "Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined signiocante: quantification by urinary pyridinium cross-links of collagen". Blood 90. 3743-3750.
  • Carlson, K., Larsson, A. Simonsson, B., Turesson. I., Weslin. J. and Ljunghall. S. (1999) "Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/crealinine (DPD) and serum ICTP. and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios". Eur, J. Haematol. 62, 300-306.
  • Carlson, K., Ljunghall. S., Simonsson, B. and Smedmyr. B. (1992) "Serum oslcocalcin concentrations in patients with multiple myeloma-correlation with disease stage and survival", J. Int. Med. 231, 133-137
  • Withold, W., Wolf. H-H., Kolbach. S., Heyll. A., Schneider, W. and Reinauer. H. (1996) "Monitoring of bone metabolism after bone marrow transplantation by measuring two different markers of bone turnover". Ear J. Clin. Chem. Clin. Biochem. 34, 193-197.
  • Stern, J.M., Chesnul, C.H., 3rd., Bruemmer, B., Sullivan. K.M., Lenssen, P.S., Aker, S.N. and Sanders. J. (1996) "Bone density loss during treatment of clironic GVHD". Bone Marrow Trans. 17. 395-4(K).
  • Bhatia, S., Ramsay. N.K.C., Weisdorf. D., Griffiths, H. and Robison. L.L. (1998) "Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies". Bone Marrow Trans. 22, 87-90.
  • Kashyap, A., Kandeel, F., Yamauchi. D., Palmer. J.M., Niland, J.C., Molina. A., Kung, H., Bhatia. R., Krishnan, A., Nademanee. A., O'Donnell, M.R., Parker. P., Rodrigues. R., Snyder. D., Spielberger. R., Stein. A., Nadler. J. and Forman. S.J (2000) "Effects of allogeneic bone marrow transplantation on recipient hone mineral density: A prospective study". Biol. Blood Marrow Trans. 6. 344 351.
  • Gahrton, G., Turd. S. Ljungman. P., Blade. J., Brandt. L., Cavo. M., Facon, T., Gratwohl. A., Hageubeek. A., Jacobs, P., de Laurenzi. A., Van Lint, M., Michallet. M., Nikoskelainen, J., Reiffers, J., Samson. D., Verdonck, L., dc Wine. T. and Volin. L. (1995) "Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma". J Clin Oncol. 13, 1312-1322.
  • Thomton, C.O., Ballester. O. and Greenfield. C.B. (1996) "Progression of bone disease in multiple myeloma patients treated with high dose therapy and autologous stem cell transplantation". Blood 88 (Suppl. I). 481a.
  • Clark, R.E., Flory. A.J., Ion. E.M., Woodcock. B.E. Durham. B.H. and Fraser. W.D. (2000) "Biochemical markers of bone turnover following high dose chemotherapy and autogratting in multiple myeloma", Blood 96, 2697-2702.
  • Capparelli, C., Kostenuik, P.J., Morony, S., Starnes. C., Weimann, B., Van. C., Scully. S., Qi. M., Lacey. D.I., and Dunstan. C.R. (2000) "Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemiu of malignancy". Cancer Res. 60, 783-787.
  • Morony, S., Capparelli. C., Sarosi. t., Lacey. D.L., Dunstan. C.R. and Kostenuik. P.J. (2001) "Osteoprotegerin inhibits osleolysis and decrease; skeletal tumor burden in syngeneic and nude mouse models ot experimental bone metastasis". Canrer Res. 61. 4432-4436.
  • Bekker, P.J., Holloway. D., Nakanishi, A., Artighi, M., Leese, PT. and Dunstan, C.R. (2001) "The effect of a single dose of ostcoprtegerin in postmenopausal women", J Bone Min. Res. 16. 348-361).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.